Technology and Patents
About microRNAs and miR-7
miReven holds worldwide exclusive rights to the UWA miR-7 patents, creating a solid IP portfolio protecting the commercialisation of miR-7 as an anti-cancer therapeutic.
Our patent estate includes 4 patent families to date, 3 of which are published and have entered National Phase examination in multiple jurisdictions including the US and Europe.
Title | Publication Details | Type | Inventors | |
1 | Method of Modulation of Expression of Epidermal Growth Factor Receptor (EGF-R) involving miRNA | US 8673872-Granted EP 2061482 - Granted | Method of use miR-7 cancer (EGFR-related) | Peter Leedman Keith Giles Rebecca Webster |
2 | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors | AU 2010324530 - Granted CA 2781572 - Pending US 9051551- Granted EU 2521555 - Granted | Methods and composition for miR-7 combination therapy | Peter Leedman Keith Giles Felicity Kalinowski |
3 | Cancer therapy using miRNAs | US 9795626 - Granted EU 13847499.4 – under examination IN 4209/DELNP/2015 - pending CH 201380065503.0 - pending | Methods of use miR-7 cancer (IGFR-related, melanoma) | Peter Leedman Keith Giles Rikki Brown |